Immunogenetics of primary hyperaldosteronism: fundamental studies and their clinical prospects

Primary hyperaldosteronism (PHA) is the most common form of endocrine hypertension. Until recently, the reason for the development of this condition was believed to be the presence of genetic mutations, however, many studies declare that the disease can be polyetiologic, be the result of genetic mutations and autoimmune triggers or cell clusters of aldosterone-producing cells diffusely located in the adrenal gland at the zona glonerulosa, zona fasculata, zona reticularis, as well as directly under the adrenal capsule. Recently, the actions of autoantibodies to type 1 angiotensin II receptors have been described in patients with renal transplant rejection, with preeclampsia, and with primary hyperaldosteronism. The diagnostic role of antibodies in both forms of PHA (aldosterone-producing adenoma and bilateral hyperaldosteronism) requires clarification. Diagnosis and confirmation of the focus of aldosterone hypersecretion is a multi-stage procedure that requires a long time and economic costs. The relevance of timely diagnosis of primary hyperaldosteronism is to reduce medical and social losses. This work summarizes the knowledge about genetic mutations and presents all the original studies devoted to autoantibodies in PHA, as well as discusses the diagnostic capabilities and limitations of the available methods of primary and differential diagnosis of the disease and the prospects for therapy.

1. Dutta RK, Söderkvist P, Gimm O. Genetics of primary hyperaldosteronism. Endocr Relat Cancer. 2016;23(10):R437-454. doi: https://doi.org/10.1530/ERC-16-0055

2. Rossitto G, Regolisti G, Rossi E, et al. Elevation of Angiotensin-II Type-1-Receptor Autoantibodies Titer in Primary Aldosteronism as a Result of Aldosterone-Producing Adenoma. Hypertension. 2013;61(2):526-533. doi: https://doi.org/10.1161/HYPERTENSIONAHA.112.202945

3. Meyer LS, Gong S, Reincke M, Williams TA. Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism. Horm Metab Res. 2020;52(6):379-385. doi: https://doi.org/10.1055/a-1120-8647

4. Sabbadin C, Ceccato F, Ragazzi E, et al. Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. J Clin Hypertens. 2018;20:1313-1318. doi: https://doi.org/10.1111/jch.13351

5. Williams textbook of endocrinology (12th ed.). Philadelphia: Elsevier/Saunders. Melmed, Shlomo., Robert Hardin Williams. Williams Textbook of Endocrinology.

6. Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin-Angiotensin-Aldosterone Syst. 2010;11(1):19-31. doi: https://doi.org/10.1177/1470320309347785

7. Nishimoto K, Nakagawa K, Li D, et al. Adrenocortical Zonation in Humans under Normal and Pathological Conditions. J Clin Endocrinol Metab. 2010;95(5):2296-2305. doi: https://doi.org/10.1210/jc.2009-2010

8. Omata K, Tomlins SA, Rainey WE. Aldosterone-Producing Cell Clusters in Normal and Pathological States. Horm Metab Res. 2017;49(12):951-956. doi: https://doi.org/10.1055/s-0043-122394

9. Seidel E, Schewe J, Scholl UI. Genetic causes of primary aldosteronism. Exp Mol Med 2019;51:1-12. doi: https://doi.org/10.1038/s12276-019-0337-9

10. Vorokhobina NV, Shustov SB, Balandina KA, Galakhova RK. Genetic aspects of primary hyperaldosteronism and pheochromocytoma. Arterial Hypertension. 2017;23(3):178-185. (In Russ.). doi: https://doi.org/10.18705/1607-419X-2017-23-3-178-185

11. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone producing adenomas and secondary hypertension // Nature Genetics. 2013;45:440-444. doi: https://doi.org/10.1038/ng.2550

12. Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. J Hypertension. 2015;65(3):622-628. doi: https://doi.org/10.1161/HYPERTENSIONAHA.114.03346

13. Stindl J, Tauber P, Sterner C, et al. Pathogenesis of adrenal aldosterone producing adenomas carrying mutations of the Na(+)/K(+)-ATPase. J Endocrinology. 2015;156(12):4582-4591. doi: https://doi.org/10.1210/en.2015–1466

14. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. J Nature. 1992;355(6357):262-265. doi: https://doi.org/10.1038/355262a0

15. Lenzini L, Prisco S, Caroccia B, Rossi GP. Saga of Familial Hyperaldosteronism. Hypertension. 2018;71(6):1010-1014. doi: https://doi.org/10.1161/HYPERTENSIONAHA.118.11150

16. Li Y, Li XH, Yuan H. Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovasc Diagn Ther. 2012;2:56-62. doi: https://doi.org/10.3978/j.issn.2223-3652.2012.02.02

17. Kem DC, Li H, Velarde-Miranda C, et al. Autoimmune Mechanisms Activating the Angiotensin AT1 Receptor in “Primary” Aldosteronism. J Clin Endocrinol Metab. 2014;99(5):1790-1797. doi: https://doi.org/10.1210/jc.2013-3282

18. Seccia TM, Caroccia B, Gomez-Sanchez EP, et al. The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications. Endocr Rev. 2018;39(6):1029-1056. doi: https://doi.org/10.1210/er.2018-00060

19. Williams TA, Mulatero P, Bidlingmaier M, et al. Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension. 2015;66(2):248-253. doi: https://doi.org/10.1161/HYPERTENSIONAHA.115.05643

20. Siddiqui AH, Irani RA, Blackwell SC, et al. Angiotensin receptor agonistic autoantibody is highly prevalent in pre- eclampsia: correlation with disease severity. Hypertension. 2010;55:386-393. doi: https://doi.org/10.1161/HYPERTENSIONAHA.109.140061

21. Thway TM, Shlykov SG, Day MC, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation. 2004;110:1612-1619. doi: https://doi.org/10.1161/01.CIR.0000142855.68398.3A

22. Mottl AK, Shoham DA, North KE. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a HuGE review. Genet Med. 2008;10(8):560-574. doi: https://doi.org/10.1097/gim.0b013e3181809613

23. Monticone S, Else T, Mulatero P, Williams TA. Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Mol Cell Endocrinol. 2015;399:311-320. doi: https://doi.org/10.1016/j.mce.2014.09.015

24. Piazza M, Seccia TM, Caroccia B, et al. AT1AA (Angiotensin II Type-1 Receptor Autoantibodies). Hypertension. 2019;74(4):793-799. doi: https://doi.org/10.1161/HYPERTENSIONAHA.119.13388

25. Dragun D, Müller DN, Bräsen JH, et al . Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558-569. doi: https://doi.org/10.1056/NEJMoa035717

26. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945-952. doi: https://doi.org/10.1172/JCI4106

27. Walther T, Wallukat G, Jank A, et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005;46:1275-1279. doi: https://doi.org/10.1161/01.HYP.0000190040.66563.04

28. Yang X, Wang F, Chang H, et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens. 2008;26:1629-1635. doi: https://doi.org/10.1097/HJH.0b013e328304dbff

29. Herse F, Verlohren S, Wenzel K, et al. Prevalence of agonistic autoan- tibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009;53:393-398. doi: https://doi.org/10.1161/HYPERTENSIONAHA.108.124115

30. Zhang S, Zheng R, Yang L, et al. Angiotensin type 1 receptor autoantibody from pre- eclamptic patients induces human fetoplacental vasoconstriction. J Cell Physiol. 2013;228:142-148. doi: https://doi.org/10.1002/jcp.24113

31. Hubel CA, Wallukat G, Wolf M, et al. Agonistic angioten- sin II type 1 receptor autoantibodies in postpartum women with a his- tory of preeclampsia. Hypertension. 2007;49:612-617. doi: https://doi.org/10.1161/01.HYP.0000256565.20983.d4

32. Siddiqui AH, Irani RA, Blackwell SC, et al. Angiotensin receptor agonistic autoantibody is highly prevalent in pre- eclampsia: correlation with disease severity. Hypertension. 2010;55:386-393. doi: https://doi.org/10.1161/HYPERTENSIONAHA.109.140061

33. Dragun D. Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant. 2007;22:1819-1822. doi: https://doi.org/10.1093/ndt/gfm072

34. Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of anti- angiotensin II type-1 receptor antibodies. Am J Transplant. 2013;13:2577-2589. doi: https://doi.org/10.1111/ajt.12395

35. Sitkin II, Romanova NY, Platonova NM, et al. Adrenal vein sampling in differential diagnosis of primary aldosteronism on the example of a clinical case. Consilium Medicum. 2019;21(4):109-113. (In Russ.). doi: https://doi.org/10.26442/20751753.2019.4.190334

36. Yoneda T, Karashima S, Kometani M, et al. Impact of New Quick Gold Nanoparticle-Based Cortisol Assay During Adrenal Vein Sampling for Primary Aldosteronism. J Clin Endocrinol Metab. 2016;101(6):2554-2561. doi: https://doi.org/10.1210/jc.2016-1011

37. Rossitto G, Battistel M, Barbiero G, et al. The subtyping of primary aldosteronism by adrenal vein sampling. J Hypertens. 2018;36(2):335-343. doi: https://doi.org/10.1097/HJH.0000000000001564

38. O’Shea PM, O’Donoghue D, Bashari W, et al. C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. Clin Endocrinol (Oxf). 2019;90(5):670-679. doi: https://doi.org/10.1111/cen.13942

39. Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: https://doi.org/10.1111/joim.12831

40. Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):150-156. doi: https://doi.org/10.1097/MED.0000000000000148

41. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the Left Ventricle in Primary Aldosteronism Due to Conn’s Adenoma. Circulation. 1997;95(6):1471-1478. doi: https://doi.org/10.1161/01.CIR.95.6.1471

42. Lattanzio MR, Weir MR. Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm. Kidney360. 2020;1(10):1146-1154. doi: https://doi.org/10.34067/KID.0000922020